Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kolon Life Science Inc.

http://www.kolonls.co.kr/eng

Latest From Kolon Life Science Inc.

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

South Korea Gene Therapy

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

South Korea Gene Therapy

Clinical Data Fraud Involving CROs Attracting US Justice Department Attention

Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.

Enforcement Advertising, Marketing & Sales

Kolon TissueGene Faces Delisting In Korea On Invossa Uncertainties

Kolon TissueGene is facing delisting in South Korea after the recent revocation of approval of gene therapy Invossa, which could fuel legal action from shareholders. The company still hopes to resume Invossa trials in the US by submitting additional data demanded by the FDA.

South Korea Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Kolon Life Science Inc.
  • Senior Management
  • Woo-Sok Lee, CEO
  • Contact Info
  • Kolon Life Science Inc.
    Phone: 02 3677-4150
    Fl. 7, Kolon Tower annex, Kolon 13
    Gwachun-si,
    South Korea
UsernamePublicRestriction

Register